CD105 Antibody

Overview

CD105/Endoglin is a Type I membrane glycoprotein located on cell surfaces and is part of the TGF-beta receptor complex. This protein has been found on endothelial cells, activated macrophages, fibroblasts, and smooth-muscle cells. Endoglin has a role in the development of the cardiovascular system and in vascular remodeling. Its expression is regulated during heart development. CD105 is highly expressed in endothelial cells during tumor angiogenesis and inflammation, with weak or negative expression in vascular endothelium of normal tissues. Angiogenesis is a promising prognostic marker in a variety of tumors. Endoglin is a more specific and sensitive marker for tumor angiogenesis than CD31 or CD34, as it labels only newly-formed blood vessels and may serve as a prognostic marker for Prostate Adenocarcinoma, and cancers of the lung, stomach, breast, and brain.

This anti-CD105 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone ENG/3269, Mouse IgG2b, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: CD105
• Format: Purified
• Localization: Cell surface, cytoplasmic
• Species reactivity: Human
• Applications (listed): IHC-P
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone ENG/3269, Mouse IgG2b, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

CD105 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling CD105 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link CD105 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• IHC-P

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.